Baseline therapy | Add-on Therapy | Size¶ | Drop out§ | Mean 6MWD improvement | Mean age | Prop male | Mean STATUS | Mean 6MWD baseline | Mean PVR |
---|---|---|---|---|---|---|---|---|---|
ERA + PDE5i | Placebo* | 23 | 4 | 2.54 (16.25) | 50.30 | 0.30 | 2.96 | 342.07 | 1157.0 |
ERA + PDE5i | Imatinib | 20 | 12 | 43.7 (14.27) | 50.15 | 0.10 | 2.60 | 328.95 | 1282.1 |
ERA + Pr | Placebo | 8 | 2 | 7.81 (14.36) | 37.00 | 0.25 | 2.38 | 381.56 | 1146.6 |
ERA + Pr | Imatinib | 10 | 5 | 48.3 (16.12) | 47.20 | 0.00 | 2.80 | 331.60 | 1071.9 |
ERA + PDE5i + Pr | Placebo | 33 | 8 | −8.27 (10.47) | 47.03 | 0.18 | 2.73 | 355.79 | 1176.6 |
ERA + PDE5i + Pr | Imatinib | 27 | 15 | 33.37 (11.54) | 47.74 | 0.19 | 2.85 | 360.70 | 1232.5 |
PDE5i + Pr | Placebo | 16 | 4 | 36.03 (10.53) | 43.19 | 0.06 | 2.56 | 358.72 | 1193.9 |
PDE5i + Pr | Imatinib | 9 | 5 | 40 (14.59) | 53.00 | 0.11 | 2.78 | 380.56 | 1050.8 |